Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
Status:
Not yet recruiting
Trial end date:
2026-06-06
Target enrollment:
Participant gender:
Summary
(1) To apply Bayesian statistics to screen for the most effective treatment regimen
containing recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent
vedicitumomab (Edisil, RC48) for locally advanced or metastatic salivary gland ductal
carcinoma expressing HER2 in the near future. (2) To explore biomarkers relevant to the
efficacy of recombinant humanized anti-HER2 monoclonal antibody-MMAE-coupled vedicitumomab
(Edisil, RC48) in the treatment of HER2-expressing locally advanced or metastatic salivary
gland ductal carcinoma.